Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16112897 | 0.88 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19CYP2C8KCNH2 | |
| SCHEMBL19262430 | 0.87 | CYP3A4 (0.38) | CYP3A4CYP2C9CYP2C19CYP2C8KCNH2 | |
| SCHEMBL16113159 | 0.86 | CYP3A4 (0.38) | CYP3A4CYP2C9CYP2C19CYP2C8KCNH2 | |
| SCHEMBL17453371 | 0.83 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2C19CYP2C8KCNH2 | |
| SCHEMBL16133806 | 0.82 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2C19CYP2C8KCNH2 | |
| SCHEMBL19262344 | 0.79 | CYP3A4 (0.39) | CYP3A4CYP2C9CYP2C19CYP2C8KCNH2 | |
| SCHEMBL19262407 | 0.78 | CYP3A4 (0.39) | CYP3A4CYP2C9CYP2C19CYP2C8KCNH2 | |
| SCHEMBL18809296 | 0.77 | CYP3A4 (0.39) | CYP3A4CYP2C9CYP2C19CYP2C8KCNH2 | |
| SCHEMBL19262420 | 0.77 | CYP3A4 (0.38) | CYP3A4CYP2C9CYP2C19CYP2C8KCNH2 | |
| SCHEMBL14217309 | 0.77 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19CYP2C8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738653-B2 | Fused furans for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| EP-2970174-B1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | disclosed |